Summary of Recent Developments for Suzhou Zelgen Biopharmaceutical Co. Ltd
| Item | Details |
|---|---|
| Market listing | Shanghai Stock Exchange (CNY) |
| Last closing price (2025‑11‑10) | 97.19 CNY |
| 52‑week range | 58.00 – 134.17 CNY |
| Market cap | 26,260,000,000 CNY |
| Price‑to‑earnings ratio | –178.95 (negative earnings) |
| Business focus | Development and production of recombinant proteins and vaccines |
1. Stock Performance Highlights (2025‑11‑12)
Intraday trading
The share price closed at 99.27 CNY after a 2.14 % gain, with a turnover of 50.13 million CNY and a turnover rate of 0.19 %.
Net inflow of institutional capital amounted to 88.02 k CNY; a large‑order purchase of 265.97 k CNY represented 5.31 % of the total inflow.
The stock’s 52‑week high remains 134.17 CNY and its low is 58.00 CNY.
ETF linkage
In the Shanghai Stock Exchange Science and Technology Innovation Board 100 Index (科创100) component list, Zelgen Biopharmaceutical registered a 4.05 % rise in the 588030 ETF on 12 November 2025.
The same ETF recorded a 0.92 % decline on the day, but had a cumulative 14.60 % gain over the previous three months.
The ETF’s trading volume on 12 November reached 95.63 million CNY, with a daily turnover rate of 1.7 %.
Day‑before activity
On 11 November 2025, the stock traded at 97.25 CNY, reflecting a 2.02 % decline, and was part of the 588030 ETF’s 0.15 % rise that day.
2. Recent Financial Results (2025)
| Period | Revenue | Net profit (loss) | YoY change |
|---|---|---|---|
| 2025 Q1‑Q3 | 5.93 billion CNY | –93.416 million CNY | Revenue +54.49 %; loss +4.58 % |
- The company reported a 54.49 % increase in operating revenue year‑to‑date, driven by sales of pharmaceutical products (99.97 % of total revenue).
- Net profit remained negative, recording a loss of 93.416 million CNY.
3. Shareholder and Institutional Holdings
- Number of shareholders: 8,809 (up 0.16 % from the prior period).
- Top institutional investors (as of 30 September 2025):
- China Europe Medical Health (A‑class) – 7.0757 million shares.
- ICBC Front‑line Medical (A‑class) – 4.70 million shares.
- Huixin Fund (Innovation Pharma) – 4.4122 million shares.
- Fujian Precise Medical – 3.6383 million shares.
4. Market and Industry Context
- Biopharmaceutical sector: The company operates in a rapidly evolving sector focused on recombinant proteins and vaccines.
- Peer performance: Within the same ETF, other biotech constituents such as Jinbi Biopharm, Banshi Bio, and Zhongjian Biopharm showed mixed performance, ranging from gains of 7.67 % to declines of 10.37 % on the same day.
- Industry sentiment: Positive investor sentiment toward biotech and innovative medicine is reflected in the ETF’s overall upward trajectory over the past three months.
5. Key Takeaways
- Stock movement: The share price increased modestly on 12 November 2025, supported by net institutional inflows and inclusion in a sector‑focused ETF that has experienced a multi‑month rally.
- Financial health: Revenue growth is strong, but profitability remains negative, consistent with the company’s investment phase in drug development.
- Market positioning: The company’s performance aligns with broader biotech trends, yet its valuation remains sensitive to earnings outcomes, as indicated by the negative P/E ratio.
These facts provide a concise overview of Suzhou Zelgen Biopharmaceutical Co. Ltd’s recent trading activity, financial performance, and market context.
